Qol Holdings Co. Achieves Record-High Sales and Profit in Q2 FY2026
I'm PortAI, I can summarize articles.
Qol Holdings Co. reported record-high sales and profit for Q2 FY2026, driven by its acquisition of a larger stake in DAIICHI SANKYO ESPHA CO., LTD. and increased use of generic drugs. The pharmacy, BPO contracting, and pharmaceutical manufacturing sectors all experienced growth, aided by new product launches and higher demand for contract medical representatives. The company has a strong presence in the Japanese pharmaceutical market, with a current market cap of Yen72.3B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments